BAY1125976 free base · Synonyms: BAY-1125976 · BAY 1125976

BAY1125976, a chemical probe, is a selective allosteric Akt1/Akt2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at…

For research use only. Not for human or veterinary use.

Target Akt

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

BAY1125976 structure

CAS No.: 1402608-02-9

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
50 mg	USD 450.00	BP-02220-50mg	In stock	Get quote
100 mg	USD 650.00	BP-02220-100mg	In stock	Get quote
250 mg	USD 1,100.00	BP-02220-250mg	In stock	Get quote
1 g	USD 2,100.00	BP-02220-1g	In stock	Get quote

Need another size or custom synthesis? Request a quote.

Description

BAY1125976, a chemical probe, is a selective allosteric Akt1/Akt2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively.

Biological activity

In Vitro BAY 1125976 is equally potent against Akt1 (IC50=5.2 nM at 10 μM ATP and 44 nM at 2 mM ATP) and Akt2 (IC50=18 nM at 10 μM ATP and 36 nM at 2 mM ATP) isoforms and up to 86 fold less potent against Akt3 (IC50=427 nM at 10 μM ATP). It inhibits the Akt1 and Akt2 by binding into an allosteric binding pocket formed by kinase and PH domain. It inhibits cell proliferation in a broad panel of human cancer cell lines, particularly in breast and prostate cancer cell lines expressing estrogen or androgen receptors. It effectively blocks Akt signaling by inhibiting the phosphorylation of Akt and the downstream effectors, including eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1), glycogen synthase kinase 3 beta (GSK3s), proline-rich Akt substrate 40 kDa (PRAS40), S6 ribosomal protein (S6RP), and 70 kDa ribosomal protein S6 kinase 1 (70S6K) In Vivo BAY 1125976 targets tumors displaying activation of the PI3K/Akt/mTOR pathway. BAY 1125976 exhibits strong in vivo efficacy in both cell line and patient-derived xenograft models such as the KPL4 breast cancer model (PIK3CAH1074R mutant), the MCF7 and HBCx-2 breast cancer models, and the AktE17K mutant driven prostate cancer (LAPC-4) and anal cancer (AXF 984) models

Identifiers

SMILES: NC(=O)C1=NN2C(C=C1)=NC(=C2C1=CC=CC=C1)C1=CC=C(C=C1)C1(N)CCC1
InChIKey: JBGYKRAZYDNCNV-UHFFFAOYSA-N

Specifications

MW (average): 383.4457
Formula: C₂₃H₂₁N₅O
CAS No.: 1402608-02-9
Physical state: Solid
Color: Light yellow to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 3 years; 4℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

In vitro: DMSO : 25 mg/mL

Documents

References

[1].Politz O, et al. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. Int J Cancer. 2017 Jan 15;140(2):449-459.

Same target

Search Akt

BP-01938 Clifutinib free base · >98%

Same research area

Search Cancer